China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will ...
SHANGHAI (Reuters) - Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, ...
, opens new tab weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%. Lilly said it expects significant production ...
Wednesday, Eli Lilly And Co (NYSE:LLY) released topline results from SURMOUNT-OSA phase 3 trials of tirzepatide in obstructive sleep apnea (OSA), a sleep-related breathing disorder characterized by ...
Eli Lilly & Co. said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced the severity of ...
Eli Lilly's (NYSE: LLY) Zepbound has shown it has what it takes to become a blockbuster. The weight-loss drug, following regulatory approval late last year, brought in $175 million in revenue in ...
Tuesday, Eli Lilly And Co (NYSE:LLY) reported first-quarter revenue of $8.77 billion, up 26% year over year, marginally missing the consensus of $8.92 billion, driven by increases of 16% in volume and ...
Eli Lilly has seen a surge in demand for its weight-loss drug Zepbound, leading to the company raising its annual sales forecast by $2 billion. The increased demand and manufacturing capacity for ...
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) made an announcement on Wednesday regarding the positive outcome of the SURMOUNT-OSA phase-3 clinical trial, which tested the effectiveness of the ...
We raise our Eli Lilly fair value estimate to $540 from $500 following stronger-than-expected first-quarter results. In particular, pricing drove 10 percentage points of the 26% top-line growth ...
Eli Lily’s weight-loss drug tirzepatide has been shown to “significantly” reduce sleep apnoea severity, the US drugs giant said on Wednesday. The firm said phase 3 clinical trials had showed ...